RNA Drug Firms Attract Deals | January 20, 2014 Issue - Vol. 92 Issue 3 | Chemical & Engineering News
Volume 92 Issue 3 | p. 11 | News of The Week
Issue Date: January 20, 2014

RNA Drug Firms Attract Deals

Pharmaceuticals: Recent successes help boost emerging therapeutic field
Department: Business
Keywords: RNA interference, biopharmaceuticals, antisense, collaboration

Small companies developing RNA-based therapeutics are finding eager partners. In less than a week, Alnylam Pharmaceuticals, Santaris Pharma, and Moderna Therapeutics announced drug development agreements totaling more than $1 billion.

The deals follow a year of significant accomplishments, says Cowen & Co. stock analyst Nicholas Bishop. He points to advances in RNA drug delivery and FDA approval of the first RNA-based drug, the cholesterol fighter Kynamro developed by Isis Pharmaceuticals and

You Do Not Have Access to C&EN Protected Content.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society